<DOC>
	<DOCNO>NCT02341404</DOCNO>
	<brief_summary>The primary aim study characterize quantify histopathological change surgical specimen obtain patient undergo prostatectomy addition imaging change ( MRI ) follow single injection Liproca Depot patient localized prostate cancer .</brief_summary>
	<brief_title>A Study 2-hydroxyflutamide ( Liproca Depot ) , Injected Into Prostate Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>The primary aim study characterize quantify histopathological change surgical specimen obtain patient undergo prostatectomy addition imaging change ( MRI ) follow single injection Liproca Depot patient localized prostate cancer . The secondary aim ere evaluate efficacy safety single injection Liproca Depot , follow pharmacokinetic profile .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hydroxyflutamide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>1 . Age ≥ 50 year , ≤ 75 year 2 . Histologically confirm localize ( stage T1c , T2aT2c ) prostate cancer judge relevant prostatectomy . 3 . PSA value &lt; 20 ng/ml within 6 week enrolment . 4 . Gleason score ≤ 3+4 diagnostic biopsy ( preferably precise method judge localization primary tumour focus ( focus ) . 5 . Adequate renal function : Creatinine &lt; 1.5 time upper limit normal . 6 . Adequate hepatic function : Aspartate Transaminase ( ASAT ) , Alanine Transaminase ( ALAT ) Alkalase Phosphatase ( ALP ) &lt; 1.5 time upper limit normal . 7 . Negative dipstick bacteriuria . 8 . Patient must ability cope study procedure return schedule visit include follow visit . 9 . Patients schedule prostatectomy 1 . Ongoing previous hormone therapy prostate cancer . 2 . Ongoing previous therapy within 12 month finasteride dutasteride . 3 . Ongoing previous invasive therapy benign prostate hyperplasia ( TURP , TUMT ) . 4 . Use pace maker electronic device 5 . Symptoms sign acute prostatitis . 6 . Symptoms sign ulcered proctitis 7 . Severe micturation symptom 8 . Ongoing therapy anticoagulant ( e.g Warfarin . Other anticoagulant withdrawn 1 week injection ) . 9 . Concomitant systemic treatment corticosteroid , immune modulating agent . 10 . Known immunosuppressive disease ( e.g . HIV , diabetes ) . 11 . Simultaneous participation study involve market authorize drug participate study within last 12 month prior start study treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>